Friday, April 29, 2022

After WHO trial failure, influential medical group advises against Gilead’s remdesivir in COVID critical care: Reuters


Gilead’s remdesivir, now known as Veklury, is perhaps the most successful COVID-19 drug so far. It scored a full FDA nod in October after months of emergency use and brought in $873 million last quarter as the standard of care in hospitalized patients.

But there are questions about how well Veklury works—and now, an influential European medical association says it shouldn’t be used in intensive care units.

In the wake of a large World Health Organization study showing no benefit for the medicine in hospitalized patients, remdesivir is “now classified as a drug you should not use routinely in COVID-19 patients” requiring critical care, Jozef Kesecioglu, president of the European Society of Intensive Care Medicine, told Reuters. 

Free Webinar

Hindsight is so 2020 – Getting Ahead of CNS Trial Enrollment in a Rapidly Changing Clinical Landscape

The past six months have highlighted both existing and unexpected enrollment challenges, as sponsors, CROs, and sites have been pressed to evolve their recruitment strategies. Join us as Rho experts discuss their approach to adapting CNS trial enrollment to a rapidly changing clinical landscape. Register now.

The group, along with the U.S. Society of Critical Care Medicine, plans to present the recommendations in an upcoming paper about COVID-19 medicines, Kesecioglu told the news service. In the first version of the paper, back in March, the experts said there wasn’t enough data to recommend the med yet. 

Gilead told Reuters in a statement it’s “confident that doctors on the front lines recognize the clinical benefit of Veklury based on robust evidence from multiple randomized, controlled studies.” 

RELATED: Gilead scored a full FDA approval for COVID-19 drug Veklury, but experts aren’t convinced

ESICM represents thousands of intensive care doctors in more than 100 countries. While its doctors aren’t required to follow recommendations, the group’s stance could reduce overall remdesivir use, Reuters reports. 

The episode is the latest dramatic turn in a months-long debate over evolving data on Veklury.

Controlled trials have shown Veklury is associated with “clinically meaningful improvements across multiple outcome assessments” in hospitalized patients, Gilead said at the time of its FDA approval last month. Those data have led doctors to turn to the medicine as the standard of care for hospitalized patients, the company added.

But a week before the FDA approval, a large World Health Organization study found the medicine “appeared to have little or no effect” in patients hospitalized with COVID-19. Gilead hit back at the results, saying the data hadn’t “undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

RELATED: Gilead Sciences takes back remdesivir distribution as demand drops

Plus, because the trial prioritized broad access, there were so many variables in the patient population that it’s “unclear if any conclusive findings can be drawn from the study results,” the company said. 

Despite the debate, the medicine has been in high demand throughout the pandemic, causing supplies to run low at times. Doctors used the Gilead drug and other medicines in treating President Donald Trump, and in the third quarter, Gilead reported $873 million in sales from the medicine. 



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...